Pharmaceuticals

A significant trend in the Next Generation Drug Conjugates Market is strategic partnerships accelerating innovation

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Next Generation Drug Conjugates Market In 2026 And What Value Is Projected For 2030?

The next generation drug conjugates market size has experienced rapid growth in recent years. Projections show it will increase from $2.47 billion in 2025 to $2.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.5%. This market’s past expansion can be linked to the limitations of conventional chemotherapy, breakthroughs in biologics research, a higher incidence of cancer, the expansion of specialty pharma companies, and the clinical effectiveness of initial drug conjugates.

The next generation drug conjugates market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $5.1 billion by 2030, achieving a compound annual growth rate (CAGR) of 15.7%. This growth during the forecast period is attributable to the wider application of personalized medicine, the expanding pipelines of oncology drugs, advancements in linker and payload chemistry, increased investments in research and development, and a rise in regulatory approvals. Significant trends expected during this period include the increasing uptake of targeted drug delivery systems, a greater emphasis on precision oncology therapies, the evolution of advanced payload technologies, the growing clinical utilization of conjugated therapeutics, and a heightened demand for drugs that offer both safety and high efficacy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19124&type=smp

What Key Drivers Are Influencing The Growth Of The Next Generation Drug Conjugates Market?

The increasing incidence of cancer is anticipated to spur the expansion of the next-generation drug conjugates market moving forward. Cancer is defined as a collection of diseases characterized by the unregulated proliferation and spread of abnormal cells within the body. The escalation in cancer cases is primarily attributed to an aging demographic, various lifestyle influences, environmental exposures, enhanced diagnostic methods, genetic predispositions, and certain infectious agents. Next-generation drug conjugates contribute to combating cancer by delivering targeted treatments directly to cancerous cells, thereby boosting treatment effectiveness while minimizing harm to healthy tissues. For example, in February 2025, according to Cancer Australia, an Australia-based government agency, there were 4,641 new pancreatic cancer cases in 2024, with 2,414 in males and 2,227 in females, indicating an increase from 3,968 cases in 2023. Thus, the escalating prevalence of cancer is propelling the growth of the next-generation drug conjugates market.

What Are The Key Segments Of The Next Generation Drug Conjugates Market?

The next generation drug conjugates market covered in this report is segmented –

1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate

2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles

3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule

4) By Therapy: Monotherapy, Combination Therapy

5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications

Subsegments:

1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides

2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates

3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates

4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates

What Key Trends Are Influencing The Development Of The Next Generation Drug Conjugates Market?

Major companies operating in the next-generation drug conjugates market are actively pursuing strategic partnerships to bolster their research and development capabilities, accelerate the introduction of new products, and expand their market footprint. These strategic alliances involve companies leveraging each other’s distinct strengths and resources to achieve mutual advantages and successful outcomes. For example, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, formed a partnership with AbCellera Biologics Inc., a Canada-based biotechnology firm. This collaboration is dedicated to the discovery, development, and commercialization of innovative antibody-drug conjugates (ADCs) for oncology, beginning with a program targeting a SMARCA degrader connected to a novel antibody. This strategic move is intended to broaden the therapeutic applications of Prelude’s small-molecule SMARCA2 selective degraders, making them available to a wider patient group, especially those with cancers not linked to SMARCA4 mutations.

Who Are The Leading Companies Operating In The Next Generation Drug Conjugates Market?

Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

Read the full next generation drug conjugates market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-drug-conjugates-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Next Generation Drug Conjugates Market?

North America was the largest region in the next generation drug conjugates market in 2025. The regions covered in the next generation drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Drug Conjugates Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19124&type=smp

Browse Through More Reports Similar to the Global Next Generation Drug Conjugates Market 2026, By The Business Research Company

Antibody Drug Conjugates Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Conjugate Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795